Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

ONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS.

Tirosh A, Killian JK, Zhu YJ, Petersen D, Walling J, Mor-Cohen R, Neychev V, Stevenson H, Keutgen XM, Patel D, Nilubol N, Meltzer P, Kebebew E.

Endocr Pract. 2019 Jun;25(6):580-588. doi: 10.4158/EP-2018-0603. Epub 2019 Mar 13.

PMID:
30865533
2.

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.

Park C, Ha SY, Kim ST, Kim HC, Heo JS, Park YS, Lauwers G, Lee J, Kim KM.

Oncotarget. 2016 Jan 26;7(4):4024-35. doi: 10.18632/oncotarget.6602.

3.

Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.

Zhang M, Zhao P, Shi X, Zhao A, Zhang L, Zhou L.

BMC Endocr Disord. 2017 Jul 13;17(1):39. doi: 10.1186/s12902-017-0190-6.

4.

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, Guhlke S, Biersack HJ, Sabet A.

J Nucl Med. 2014 Feb;55(2):183-90. doi: 10.2967/jnumed.113.125336. Epub 2014 Jan 16.

5.

Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.

Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davì MV, Bianchi A, Valcavi R, Papini E, Giuffrida D, Ferone D, Fanciulli G, Arnaldi G, Franchi GM, Francia G, Fasola G, Crinò L, Pontecorvi A, Tomassetti P, Colao A.

J Endocrinol Invest. 2012 Oct;35(9):817-23. doi: 10.3275/8102. Epub 2011 Nov 9.

PMID:
22080849
6.

Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.

Yoo C, Cho H, Song MJ, Hong SM, Kim KP, Chang HM, Chae H, Kim TW, Hong YS, Ryu MH, Kang YK, Kim SC, Ryoo BY.

Cancer Chemother Pharmacol. 2017 Jan;79(1):139-146. doi: 10.1007/s00280-016-3215-3. Epub 2016 Dec 10.

PMID:
27942928
7.

Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.

Backman S, Norlén O, Eriksson B, Skogseid B, Stålberg P, Crona J.

Anticancer Res. 2017 Feb;37(2):705-712.

PMID:
28179320
8.

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.

Barrea L, Altieri B, Muscogiuri G, Laudisio D, Annunziata G, Colao A, Faggiano A, Savastano S.

Nutrients. 2018 Dec 1;10(12). pii: E1854. doi: 10.3390/nu10121854.

9.

The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.

Liu CT, Chen MH, Chen JS, Chen LT, Shan YS, Lu CH, Su YL, Ku FC, Chou WC, Chen YY.

Asia Pac J Clin Oncol. 2016 Dec;12(4):396-402. doi: 10.1111/ajco.12571. Epub 2016 Jun 30.

PMID:
27357443
10.

Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era.

Kim ST, Lee SJ, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS.

J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016.

11.

Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany.

Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K, Zappe SM.

World J Gastroenterol. 2013 Dec 21;19(47):9012-9. doi: 10.3748/wjg.v19.i47.9012.

12.

BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma.

Dizdar L, Werner TA, Drusenheimer JC, Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W, Esposito I, Stoecklein NH, Knoefel WT, Krieg A.

Int J Cancer. 2019 Mar 15;144(6):1379-1390. doi: 10.1002/ijc.31828. Epub 2018 Oct 30.

PMID:
30144031
13.

Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.

Goretzki PE, Mogl MT, Akca A, Pratschke J.

Rev Endocr Metab Disord. 2018 Jun;19(2):169-178. doi: 10.1007/s11154-018-9469-9. Review.

PMID:
30280290
14.

Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.

Li J, Lu M, Lu Z, Li Z, Liu Y, Yang L, Li J, Zhang X, Zhou J, Wang X, Gong J, Gao J, Li Y, Shen L.

Oncotarget. 2017 Apr 11;8(15):25669-25678. doi: 10.18632/oncotarget.12900.

15.

Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.

Jiménez-Fonseca P, Carmona-Bayonas A, Martín-Pérez E, Crespo G, Serrano R, Llanos M, Villabona C, García-Carbonero R, Aller J, Capdevila J, Grande E; Spanish Neuroendocrine Tumor Group (GETNE).

Cancer Metastasis Rev. 2015 Sep;34(3):381-400. doi: 10.1007/s10555-015-9573-1. Review.

PMID:
26245646
16.

Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story?

Delaunoit T, Van den Eynde M, Borbath I, Demetter P, Demolin G, Pattyn P, Pauwels S, Peeters M, Roeyen G, Van Cutsem E, Van Hootegem P, Van Laethem JL, Verslype C, Hendlisz A.

Acta Gastroenterol Belg. 2009 Jan-Mar;72(1):49-53. Review.

PMID:
19402372
17.

Copy number alterations in small intestinal neuroendocrine tumors determined by array comparative genomic hybridization.

Hashemi J, Fotouhi O, Sulaiman L, Kjellman M, Höög A, Zedenius J, Larsson C.

BMC Cancer. 2013 Oct 29;13:505. doi: 10.1186/1471-2407-13-505.

18.

Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms.

Görtz B, Roth J, Krähenmann A, de Krijger RR, Muletta-Feurer S, Rütimann K, Saremaslani P, Speel EJ, Heitz PU, Komminoth P.

Am J Pathol. 1999 Feb;154(2):429-36.

19.

CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?

Luo Y, Chen J, Shen B, Wang M, Cai H, Xu L, Chen L, Chen M, Li ZP, Feng ST.

Eur Radiol. 2018 Dec;28(12):5250-5257. doi: 10.1007/s00330-018-5512-1. Epub 2018 Jun 6.

PMID:
29876704
20.

Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.

Sevilla I, Segura Á, Capdevila J, López C, García-Carbonero R, Grande E; GETNE (Spanish Group of NeuroEndocrine Tumors).

BMC Cancer. 2016 Nov 7;16(1):858.

Supplemental Content

Support Center